| Dr Giacomo Pierce Folden, DO | |
|
1000 Harrington St, Mount Clemens, MI 48043-2920 | |
| (586) 493-8000 | |
| Not Available |
| Full Name | Dr Giacomo Pierce Folden |
|---|---|
| Gender | Male |
| Speciality | General Practice |
| Experience | 9 Years |
| Location | 1000 Harrington St, Mount Clemens, Michigan |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1215310073 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 5101021551 (Michigan) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Ascension Providence - Crittenton Hospital Medical Center | Rochester, MI | Hospital |
| Ascension St John Hospital | Detroit, MI | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Ascension Providence Rochester Hospital | 8820994098 | 88 |
News Archive
"Health ministers from Swaziland and South Africa have agreed to radically change the diagnosis and treatment of the co-epidemic of [tuberculosis (TB)]/HIV in their countries," VOA News reports.
Melbourne researchers have discovered that anti-cancer compounds currently in clinical trials for some types of leukaemia could offer hope for treating the most common type of breast cancer.
DARA BioSciences, Inc. announced today that on April 26, 2010, DARA Therapeutics, a subsidiary of DARA BioSciences, and the Division of Cancer Prevention, National Cancer Institute (NCI), National Institutes of Health (NIH), entered into a Clinical Trials Agreement to advance the clinical study of KRN5500 for the treatment of Chemotherapy Induced Peripheral Neuropathy (CIPN) in patients with cancer. Under the terms of the collaboration, NCI will fund the studies and DARA will supply KRN5500 and placebo.
By altering a molecule called Stat1, which is involved in cellular immune signaling, scientists have succeeded in making the molecule more responsive and thus more efficient. This old protein with a new twist may eventually be used to improve the body's defense against infection.
› Verified 1 days ago
| Entity Name | Ascension Medical Group Michigan |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1942317631 PECOS PAC ID: 0648180406 Enrollment ID: O20031113000362 |
News Archive
"Health ministers from Swaziland and South Africa have agreed to radically change the diagnosis and treatment of the co-epidemic of [tuberculosis (TB)]/HIV in their countries," VOA News reports.
Melbourne researchers have discovered that anti-cancer compounds currently in clinical trials for some types of leukaemia could offer hope for treating the most common type of breast cancer.
DARA BioSciences, Inc. announced today that on April 26, 2010, DARA Therapeutics, a subsidiary of DARA BioSciences, and the Division of Cancer Prevention, National Cancer Institute (NCI), National Institutes of Health (NIH), entered into a Clinical Trials Agreement to advance the clinical study of KRN5500 for the treatment of Chemotherapy Induced Peripheral Neuropathy (CIPN) in patients with cancer. Under the terms of the collaboration, NCI will fund the studies and DARA will supply KRN5500 and placebo.
By altering a molecule called Stat1, which is involved in cellular immune signaling, scientists have succeeded in making the molecule more responsive and thus more efficient. This old protein with a new twist may eventually be used to improve the body's defense against infection.
› Verified 1 days ago
| Entity Name | Ascension Providence Rochester Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1366565442 PECOS PAC ID: 8820994098 Enrollment ID: O20071117000068 |
News Archive
"Health ministers from Swaziland and South Africa have agreed to radically change the diagnosis and treatment of the co-epidemic of [tuberculosis (TB)]/HIV in their countries," VOA News reports.
Melbourne researchers have discovered that anti-cancer compounds currently in clinical trials for some types of leukaemia could offer hope for treating the most common type of breast cancer.
DARA BioSciences, Inc. announced today that on April 26, 2010, DARA Therapeutics, a subsidiary of DARA BioSciences, and the Division of Cancer Prevention, National Cancer Institute (NCI), National Institutes of Health (NIH), entered into a Clinical Trials Agreement to advance the clinical study of KRN5500 for the treatment of Chemotherapy Induced Peripheral Neuropathy (CIPN) in patients with cancer. Under the terms of the collaboration, NCI will fund the studies and DARA will supply KRN5500 and placebo.
By altering a molecule called Stat1, which is involved in cellular immune signaling, scientists have succeeded in making the molecule more responsive and thus more efficient. This old protein with a new twist may eventually be used to improve the body's defense against infection.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Giacomo Pierce Folden, DO 1000 Harrington St, Mount Clemens, MI 48043-2920 Ph: () - | Dr Giacomo Pierce Folden, DO 1000 Harrington St, Mount Clemens, MI 48043-2920 Ph: (586) 493-8000 |
News Archive
"Health ministers from Swaziland and South Africa have agreed to radically change the diagnosis and treatment of the co-epidemic of [tuberculosis (TB)]/HIV in their countries," VOA News reports.
Melbourne researchers have discovered that anti-cancer compounds currently in clinical trials for some types of leukaemia could offer hope for treating the most common type of breast cancer.
DARA BioSciences, Inc. announced today that on April 26, 2010, DARA Therapeutics, a subsidiary of DARA BioSciences, and the Division of Cancer Prevention, National Cancer Institute (NCI), National Institutes of Health (NIH), entered into a Clinical Trials Agreement to advance the clinical study of KRN5500 for the treatment of Chemotherapy Induced Peripheral Neuropathy (CIPN) in patients with cancer. Under the terms of the collaboration, NCI will fund the studies and DARA will supply KRN5500 and placebo.
By altering a molecule called Stat1, which is involved in cellular immune signaling, scientists have succeeded in making the molecule more responsive and thus more efficient. This old protein with a new twist may eventually be used to improve the body's defense against infection.
› Verified 1 days ago
Mrs. Donyelle Moore-baldwin, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 18 Market St Ste C, Mount Clemens, MI 48043 Phone: 586-783-2222 Fax: 583-783-6380 | |
Gladstone Anthony Payton Sr., DO Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 247 N Gratiot Ave, Mount Clemens, MI 48043 Phone: 586-468-8088 Fax: 586-468-8283 | |
Dr. Joseph Thomas Naughton, D.O. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 18 Market St Ste C, Mount Clemens, MI 48043 Phone: 586-783-2222 | |
Dr. William Matthew Jacobs, D.O. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1000 Harrington St, Mount Clemens, MI 48043 Phone: 586-493-8000 | |
Taylor Rae Roach, DO Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1000 Harrington St, Mount Clemens, MI 48043 Phone: 586-493-8142 Fax: 586-493-3250 | |
Dr. Angelica Radzioch, D.O. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1000 Harrington St, Mount Clemens, MI 48043 Phone: 586-493-8000 |